KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Cash (2016 - 2025)

Historic Change in Cash for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $376.9 million.

  • Alnylam Pharmaceuticals' Change in Cash rose 18707.28% to $376.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $390.3 million, marking a year-over-year increase of 48004.99%. This contributed to the annual value of $153.8 million for FY2024, which is 38649.58% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Change in Cash stood at $376.9 million for Q3 2025, which was up 18707.28% from $93.6 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Change in Cash high stood at $497.7 million for Q3 2022, and its period low was -$285.9 million during Q1 2022.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Change in Cash value was $41.5 million (recorded in 2022), while the average stood at $52.3 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Change in Cash plummeted by 24926818.18% in 2021 and then soared by 208457.91% in 2024.
  • Alnylam Pharmaceuticals' Change in Cash (Quarter) stood at -$274.3 million in 2021, then rose by 24.6% to -$206.8 million in 2022, then dropped by 6.52% to -$220.3 million in 2023, then soared by 39.25% to -$133.8 million in 2024, then skyrocketed by 381.62% to $376.9 million in 2025.
  • Its last three reported values are $376.9 million in Q3 2025, $93.6 million for Q2 2025, and $53.6 million during Q1 2025.